agents in general. This is even more important since the established second line androgen-targeting drugs in use for Prostate cancer, the likes of Xtandi (enzalutamide) and Zytiga (abiraterone/prednisone) have a very high degree of cross resistance and cannot be used in sequence for a long-term manag